CMB International Global Markets | Equity Research | Company Update



招商银行全资附属机和 A Wholly Owned Subsidiary Of China Merchants Ban

Xtep (1368 HK)

Prudent on 2Q22 but guidance maintained

Xtep's numbers in 1Q22 was resilient, in our view. Management maintained its FY22E guidance but turned slightly more conservative on 2Q22E retail sales condition. Due to its rapid growth ahead and attractive valuation (20x FY22E P/E), we maintain BUY and keep our SOTP-based TP at HK\$16.21, implying ~28x FY22E P/E (unchanged).

- 1Q22 retail sales growth inline, but already strong given the pandemic in late Mar. Xtep's retail sales grew by 30-35% YoY in 1Q22, inline with cons. and slightly above CMBI est. of 28%, and even accelerated from 20-25% in 4Q21. All channel retail sales growth was fast at 35% (40%+/50%+ for e-commerce/ kids) during Jan-Feb 2022. Such trend had sustained into first 2 weeks of Mar, but offline retail sales growth slowed down to mid-teens (40%+ for e-commerce), which should be better than Li Ning and Anta according to our understanding. Inventory to sales was at 4 months, same as 4Q21 while retail sales discounts was at 25% off, slightly higher than 20-25% off in 4Q21.
- Management have become more prudent on retail sales in 2Q22E. Due to the Covid-19 outbreaks in Shanghai and Jilin, etc., logistic and supply chain was interrupted and hence both offline and e-commerce sales wwere affected. But because 2Q and April tend to be low seasons, as long as the outbreaks can be under control by 5-1 golden week, management is still confident on achieving a rather prudent 15-20% retail sales growth. Noted that 2Q22E may become more promotional with retail discounts of 25-30% off. Moreover, the size of re-orders (often accounted for 10% of sales in that quarter) could depend highly on the post pandemic recovery.
- But the guidance for listed co. was maintained. Management maintained guidance of 25-30% sales growth in FY22E (and 35-45% in 1H22E) because it has already factored in this round of COVID-19 outbreak in Shanghai and Shenzhen back in the result in Mar. Also, the supports provided so far for its distributors are rather limited (no higher rebates, no cancelled orders and no refunds, etc.), hence the negative financial impact on listed co. level is also limited. Sales and net profit guidance for the new brands were also maintained.
- Maintain BUY and keep TP at HK\$ 16.21. We maintain BUY with a TP at HK\$ 16.21, based on SOTP valuation (24x FY22E P/E for Xtep, cost for K&P and 2.0x P/S for JV), implying ~28x for group, reasonable given the 26% NP CAGR in FY21-24E.

Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	8,172	10,013	12,568	14,587	16,430
YoY growth (%)	(0.1)	22.5	25.5	16.1	12.6
Net income (RMB mn)	513	908	1,210	1,508	1,811
EPS (RMB)	0.206	0.355	0.475	0.592	0.711
YoY growth (%)	(31.6)	72.1	33.8	24.6	20.1
Consensus EPS (RMB)	n/a	n/a	0.461	0.579	0.800
P/E (x)	47.2	27.0	20.2	16.2	13.5
P/B (x)	3.4	3.1	2.9	2.6	2.4
Yield (%)	1.2	2.2	3.0	3.7	4.4
ROE (%)	7.0	11.4	14.1	16.3	18.0
Net gearing (%)	Net cash				

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price HK\$16.21 (Previous TP HK\$16.21)
Up/Downside +40.0%
Current Price HK\$11.58

China Sportswear Sector

Walter Woo

(852) 3761 8776 walterwoo@cmbi.com.hk

Raphael Tse

(852) 3900 0856 raphaeltse@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	30,459
Avg 3 mths t/o (HK\$ mn)	192.47
52w High/Low (HK\$)	16.32/4.58
Total Issued Shares (mn)	2,630.3
Source: Bloomberg	

Shareholding Structure

Mr Ding Shui Po & Family	52.28%
JP Morgan Chase	4.61%
ICBC Credit Suisse AM	3.02%
Employee incentive scheme	4.01%
Free Float	36.08%

Source: HKEx, Bloomberg

Share Performance

Absolute	Relative
0.3%	-0.5%
3.3%	7.9%
20.7%	31.0%
163.3%	245.1%
	0.3% 3.3% 20.7%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: Ernst & Young

Related Reports

- Xtep (1368 HK, BUY) Robust retail sales growth despite pandemic – 17 Mar
- Xtep (1368 HK, BUY) Upbeat guidance with multiple growth drivers – 17 Jan 2022
- Xtep (1368 HK, BUY) Slight beat in 3Q21 and guidance maintained – 20 Oct 2021



Operating numbers

Figure 1: Sportswear brands sales growth trend

Nac China case 14,0% 12,0%	Operating numbers	1Q19	2Q19	3Q19	4Q19	1Q20	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22E	2Q22E	3Q22E	4Q22E
Medical Chains Sales 14 15 15 15 15 15 15 15	Operating numbers Nike China sales													TQZZE	2Q22E	3Q22E	4Q22E
Act Description Part Section P																	
Companies Part Pa	Anta brand's SSSG																
Character Char	Anta brand's retail sales				-		-ve LSD	+ve LSD	+ve LSD	40%-45%	35%-40%			23.0%	5.0%	25.0%	25.0%
Color: 1-10	Core brand	+ve HSD			+ve HSD		-ve LSD	-ve MSD	-ve MSD	35%-40%	35%-40%	+ve HSD	+ve MSD				
Charle Part	Kids	Over 20%	30%	Over 25%	25%		+ve MSD			45%-50%	Over 20%	+ve MSD					
Classic Core branch Sept.	Online		25%	35%	Over 40%		Over 40%	Over 50%	Over 25%	Over 60%	Over 45%	25%-30%					
Classic Core brand	Non-Anta brands (FILA/	65%-70%	55%-60%														
Control Cont	FILA brand's retail sales	i		50%-55%	50%-55%	-ve MSD		20%-25%	25%-30%	75%-80%	30%-35%	+ve MSD	+ve HSD	17.0%	10.0%	20.0%	15.0%
Fusion	Classic/ Core brand				Over 40%			+ve MSD	+ve MSD	80%	Over 20%	Flat	Flat				
Public P	Kids				Over 70%	-ve LSD	Over 30%	Over 30%	Over 20%	100%	Over 40%						
Over 100	Fusion					+ve MSD	Over 70%	Over 50%	Over 50%	150%	Over 80%	+ve Mid-	+ve Low-				
Description Control of the State Contro	Online					160%	Over 80%	Over 90%	70%-80%	Over 40%	Over 40%						
Modes 100%	Other brands			30%-35%	25%-30%	-ve HSD	25%-30%	50%-55%	55%-60%		70%-75%	35%-40%	30%-35%				
Li Ning group's SSS6	Descente		Over 90%	50%	50%		Over 60%	90%	Over 80%	150%	100%	50%	40%-45%				
Linking group's SSSG teens	Kolon					-	+ve LSD	20%-25%	30%-40%	Over 75%		30%					
Subject Subj	Li Ning group's SSSG			-		n/a	-ve MSD	+ve LSD		n/a		-					
Lens	Direct retail	+ve HSD			-	n/a		-ve MSD	+ve HSD	n/a							
Li Ning group's retail sale Vec Low Vec Low Vec Mode Vec	Wholesales					n/a		-ve MSD	+ve MSD	n/a			-				
Li Ning group's retail sale +ve Low +ve Low 20%-25% 20%-25% 30%-36% 30%-46% teens 20%-25% 30%-36% 30%-46% teens 30% ve MsD ve MsD +ve MsD ve Low teens 40% 80% 80% 80% 40% 30% 40% 30% 25.0% 25.0% 20.0% 2	E- Commerce									n/a							
	Li Ning group's retail sa			+ve Low		-ve High-	-ve MSD							28.0%	5.0%	25.0%	20.0%
Wholesales	Direct retail	_					-ve Low-	Flot									
F- Commerce	Direct retail						teens	ı ıaı									
E-Commerce	Wholesales						-ve HSD	-ve LSD									
A commerce 40% 20% 50% 40% teens 20% 40% 30% 100% 90% 50% 40%							+ve High	+ve Low									
The complete The	E- Commerce									100%							
Step's retail sales Over 20%	Xten's SSSG	+ve Low-	+ve Low-	10%	+ve Low-												<u>-</u>
Second S		teens	teens		teens	- 000/				NA: 1 F00/							
The color of the	-						-ve LSD	+ve MSD	+ve HSD		30%-35%		20%-25%	30%-35%	10.0%	25.0%	20.0%
25% teens 15%-20% teens teens teens teens teens teens teens teens teens teen	361 Degrees' SSSG	+ve LSD	+ve LSD	+ve LSD	+ve LSD	va 200/	va Law			.va Hiah		uva Law	.ve High				
Pou Sheng's sales 19.9% 18.9% 21.9% 19.1% -25.1% 0.3% -0.3% 1.0% 47.8% -15.0% -25.1% -26.7% -10.0% 0.0% 10.0% 15.0%						25%	teens	-ve HSD	+ve LSD		15%-20%		_				
Vertical Flat Vertical Flat Vertical Flat Vertical								0.20/	4.00/	47.00/	45.00/	05.40/	00.70/	40.00/	0.00/	40.00/	45.00/
Dong Xiang's SSSG	rou Sneng's sales	19.9%	18.9%			-25.1%	0.3%	-0.3%	1.0%	47.8%				-10.0%	0.0%	10.0%	15.0%
Dong Xiang's retail sale +ve MSD +ve MSD +ve MSD +ve MSD +ve MSD +ve MSD +ve Low-teens -ve 25%-teens 30% Mid SD +ve MSD +ve Low-teens 60%-70% teens 60%-70% teens +ve Low-teens +ve Low-teens +ve MSD +ve MS	Dong Xiang's SSSG	-ve LSD	+ve MSD	to High	to High		-ve MSD		+ve MSD	+ve HSD	to High	-ve High-	High-				
Test +ve usb +ve nsb +ve nsb +ve nsb 35% teens 181 +ve nsb 70%-75%	Dong Xiang's retail sale	+ve MSD	+ve MSD	+ve Mid-	+ve Low-	30%		+ve MSD		60%-70%	+ve Low to Mid-	High-	-ve Mid-				
	Direct retail	Flat	+ve LSD	+ve HSD	+ve MSD			Flat		70%-75%							
	E- Commerce									35%-40%							

Source: Company data, CMBIGM estimates, *Nike's year end is in May (e.g. 4Q18 calendar year = 2Q19 fiscal year = Sep-Nov 2018)



Assumptions

Figure 2: Major assumptions

Major assumptions	FY20A	FY21A	FY22E	FY23E	FY24E
Sales by segment (RMB mn)					
Shoes	5,047	5,928	7,497	8,724	9,877
Apparels	2,964	3,887	4,859	5,637	6,313
Accessories	161	198	211	226	240
Total	8,172	10,013	12,568	14,587	16,430
Sales by segment growth (%)					
Shoes	8.5%	17.5%	26.5%	16.4%	13.2%
Apparels	-11.4%	31.2%	25.0%	16.0%	12.0%
Accessories	-12.9%	22.5%	7.0%	7.0%	6.0%
Total	-0.1%	22.5%	25.5%	16.1%	12.6%
Sales by segment (RMB mn)					
Mass market	7,101	8,841	11,038	12,748	14,225
Athleisure	999	971	1,220	1,374	1,549
Professional sports	72	201	310	465	656
Total	8,172	10,013	12,568	14,587	16,430
Sales by segment growth (YoY)					
Mass market	-7.9%	24.5%	24.8%	15.5%	11.6%
Athleisure	114.4%	-2.8%	25.7%	12.6%	12.8%
Professional sports	609.9%	180.3%	54.1%	50.2%	41.0%
Total	-0.1%	22.5%	25.5%	16.1%	12.6%
Sales network					
Xtep	4,971	4,722	4,864	5,010	5,160
Xtep kids	800	1,179	1,297	1,401	1,499
Oversea stores	250	250	300	300	300
Total	6,021	6,151	6,461	6,710	6,959
GP margins	39.1%	41.7%	42.3%	43.1%	43.3%
Opex breakdown					
A&P / sales	11.2%	10.2%	10.5%	11.0%	11.0%
Staff costs/ sales	12.1%	11.1%	10.5%	10.5%	10.4%
R&D / sales	2.7%	2.5%	2.4%	2.3%	2.3%
D&A / sales	2.0%	1.7%	1.5%	1.5%	1.4%
Provisions (write backs) / sales	0.7%	-0.2%	0.0%	0.0%	0.0%
Rental / sales	0.1%	0.1%	0.3%	0.4%	0.4%
Selling & distribution costs / sales	18.8%	18.9%	19.0%	19.3%	19.1%
Admin expenses / sales	12.9%	11.9%	11.4%	11.1%	10.9%
Total	31.7%	30.8%	30.4%	30.4%	30.0%
OP margins	11.2%	13.9%	14.4%	15.2%	15.8%
Effective tax rate	33.7%	30.9%	31.0%	30.0%	29.0%
Net profit att. margins	6.3%	9.1%	9.6%	10.3%	11.0%
Net profit att. growth (%)	-29.5%	77.1%	33.2%	24.6%	20.1%

Source: Company data, CMBIGM estimates



Valuation

Figure 3: Peers valuation table

			12m TP	Price	Up/ Down-	Mkt. Cap	Year	P/E (x)		P/E (x)		P/B	(x)	ROE (%)	3yrs PEG (x)	Yield (%)
Company	Ticker	Rating	(LC)	(LC)	side	(HK\$mn)	End	FY1E	FY2E	FY1E	FY2E	FY1E	FY1E	FY1E		
H shares Spo	<u>rtswear</u>															
Xtep Intl	1368 HK	BUY	16.21	11.58	40%	30,459	Dec-21	17.5	14.0	2.9	2.6	12.0	0.7	3.4		
Anta Sports	2020 HK	BUY	121.33	94.30	29%	254,924	Dec-21	22.4	18.0	5.8	4.7	29.2	1.0	1.8		
Li Ning	2331 HK	BUY	81.04	63.60	27%	166,431	Dec-21	27.9	22.4	5.8	4.8	26.9	1.3	1.1		
361 Degrees	1361 HK	NR	n/a	4.00	n/a	8,270	Dec-21	10.0	8.8	0.8	0.8	8.8	1.0	3.4		
Topsports	6110 HK	NR	n/a	6.47	n/a	40,122	Feb-21	11.5	9.7	2.9	2.5	26.5	0.7	4.4		
Pou Sheng	3813 HK	NR	n/a	0.90	n/a	4,794	Dec-21	5.0	3.6	0.4	0.4	4.5	0.1	3.3		
China DX	3818 HK	NR	n/a	0.47	n/a	2,767	Mar-21	n/a	3.5	0.2	0.2	(0.5)	0.0	n/a		
							Avg.	15.7	11.4	2.7	2.3	15.3	0.7	2.9		
							Med.	14.5	9.7	2.9	2.5	12.0	0.7	3.3		
International Sp	<u>portswear</u>															
Nike Inc	NKE US	NR	n/a	128.36	n/a	1,583,284	May-21	34.5	27.7	13.9	12.0	45.7	2.3	0.9		
Adidas	ADS GY	NR	n/a	205.75	n/a	338,653	Dec-21	21.2	17.5	5.4	4.8	30.3	3.4	1.9		
Puma	PUM GY	NR	n/a	73.74	n/a	95,294	Dec-21	26.7	21.0	4.6	4.0	15.7	1.2	1.2		
Under Armour	UAA US	NR	n/a	16.15	n/a	57,602	Mar-23	22.2	20.5	n/a	2.7	19.1	2.5	n/a		
Lululemon	LULU US	NR	n/a	371.83	n/a	372,777	Jan-22	39.5	33.5	13.7	10.6	36.8	2.0	0.0		
Skechers	SKX US	NR	n/a	38.63	n/a	47,246	Dec-21	13.2	10.7	1.6	1.4	25.8	(6.3)	0.0		
Vf Corp	VFC US	NR	n/a	55.75	n/a	169,931	Apr-21	17.4	15.4	6.4	5.9	41.1	0.3	3.6		
Columbia	COLM US	NR	n/a	86.40	n/a	43,687	Dec-21	15.0	13.4	2.6	2.4	18.5	1.3	1.4		
Wolverine	WWW US	NR	n/a	21.66	n/a	13,817	Jan-22	8.4	7.4	2.3	2.0	11.3	0.1	2.6		
Mizuno Corp	8022 JP	NR	n/a	2063.00	n/a	3,469	Mar-21	17.4	12.6	0.5	0.5	7.6	1.7	2.4		
Asics Corp	7936 JP	NR	n/a	2226.00	n/a	26,738	Dec-21	25.5	19.6	2.7	2.5	6.9	0.8	1.4		
							Avg.	21.9	18.1	5.4	4.4	23.5	0.9	1.5		
							Med.	21.2	17.5	3.7	2.7	19.1	1.3	1.4		

Source: Bloomberg, CMBIGM estimates



Financial Summary

Income statement						Cash flow summary					
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	8,172	10,013	12,568	14,587	16,430	EBIT	918	1,396	1,806	2,214	2,590
Footwear	5,047	5,928	7,497	8,724	9,877	D & A	78	84	132	167	182
Apparel	2,964	3,887	4,859	5,637	6,313	Change in working capital	(320)	(447)	(787)	(634)	(569)
Accessories	161	198	211	226	240	Income tax paid	(325)	(329)	(536)	(649)	(745)
						Others	(32)	(3)	(47)	(51)	(54)
Cost of goods sold	(4,973)	(5,835)	(7,255)	(8,298)	(9,310)	Net cash from operating	320	701	568	1,047	1,404
Gross profit	3,198	4,178	5,314	6,290	7,120						
Other income	307	299	314	365	394	Capex & investments	(207)	(414)	(440)	(511)	(575)
						Associated companies	(20)	-	-	-	-
Operating expenses	(2,588)	(3,081)	(3,822)	(4,440)	(4,924)	Interest received	-	-	-	-	-
S & D costs	(1,537)	(1,891)	(2,385)	(2,819)	(3,137)	Others	800	86	-	-	-
Admin exp.	(827)	(937)	(1,135)	(1,285)	(1,410)	Net cash from investing	573	(329)	(440)	(511)	(575)
R & D	(223)	(252)	(302)	(336)	(378)						
Other operating expenses	-	-	-	-	-	Equity raised	31	-	-	-	-
EBIT	918	1,396	1,806	2,214	2,590	Net change in bank loans	(77)	(312)	-	-	-
						Dividend paid	(279)	(356)	(628)	(808)	(988)
Finance costs, net	(140)	(63)	(47)	(51)	(54)	Others	(55)	764	-	-	-
JVs & associates	(17)	(46)	(31)	-	33	Net cash from financing	(380)	96	(628)	(808)	(988)
Exceptional	-	-	-	-	-						
Pre-tax profit	762	1,287	1,728	2,163	2,569	Net change in cash	513	469	(500)	(271)	(160)
						Beginning cash balance	2,970	3,472	3,930	3,430	3,159
Income tax	(257)	(397)	(536)	(649)	(745)	Exchange difference	(11)	(11)	-	-	-
Less: Minority interests	(8)	(19)	(17)	6	13	Cash at the end of the year	3,472	3,930	3,430	3,159	2,999
Net profit	513	908	1,210	1,508	1,811						

Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY20A	FY21A	FY22E	FY23E	FY24E	YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Non-current assets	3,544	4,183	4,460	4,804	5,230	Sales mix (%)					
Fixed asset	796	1,119	1,452	1,836	2,282	Footwear	61.8	59.2	59.7	59.8	60.1
Intangible assets & goodwill	741	700	674	634	582	Apparel	36.3	38.8	38.7	38.6	38.4
Prepaid lease payments	573	576	576	576	576	Accessories	2.0	2.0	1.7	1.6	1.5
Interest in joint ventures	218	365	334	334	366		-	-	-	-	-
Other non-current assets	1,216	1,424	1,424	1,424	1,424	Total	100.0	100.0	100.0	100.0	100.0
Current assets	9,027	10,432	11,565	12,564	13,579	P&L ratios (%)					
Cash and cash equivalents	3,472	3,930	3,430	3,159	2,999	Gross margin	39.1	41.7	42.3	43.1	43.3
Inventories	975	1,497	1,862	2,129	2,389	Operating margin	11.2	13.9	14.4	15.2	15.8
Trade and other receivables	3,236	3,528	4,429	5,140	5,789	Pre-tax margin	9.3	12.9	13.8	14.8	15.6
Prepayments	899	1,443	1,811	2,102	2,367	Net margin	6.3	9.1	9.6	10.3	11.0
Other current assets	446	34	34	34	34	Effective tax rate	33.0	29.8	30.5	30.0	29.4
Current liabilities	3,334	4,053	4,898	5,535	6,140	Balance sheet ratios					
Bank loans	642	405	405	405	405	Current ratio (x)	2.7	2.6	2.4	2.3	2.2
Trade payables	1,479	2,352	2,925	3,345	3,753	Quick ratio (x)	2.4	2.2	2.0	1.9	1.8
Accruals & other payables	1,052	1,071	1,344	1,560	1,757	Cash ratio (x)	1.0	1.0	0.7	0.6	0.5
Tax payables	86	123	123	123	123	Inventory turnover days	72	94	94	94	94
Others	75	102	102	102	102	Trade receivables days	145	129	129	129	129
						Trade payables days	109	147	147	147	147
Non-current liabilities	1,939	2,580	2,580	2,580	2,580	Total debt / total equity ratio (%)	30	32	30	27	25
Bank loans	1,516	1,375	1,375	1,375	1,375	Net debt / equity ratio (%)	Net cash				
CB or Preferred shares	-	758	758	758	758	Returns (%)					
Deferred tax	237	253	253	253	253	ROE	7.0	11.4	14.1	16.3	18.0
Others	186	194	194	194	194	ROA	4.1	6.2	7.5	8.7	9.6
						Per share					
Minority Interest	-	-	-17	-11	2	EPS (RMB)	0.21	0.36	0.48	0.59	0.71
Total net assets	7,299	7,982	8,564	9,264	10,086	DPS (RMB)	0.12	0.21	0.29	0.36	0.43
Shareholders' equity	7,299	7,982	8,564	9,264	10,086	BVPS (RMB)	2.87	3.13	3.36	3.64	3.96

Source: Company data, CMBIGM estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY
Stock with potential return of over 15% over next 12 months
SELL
Stock with potential return of +15% to -10% over next 12 months
SELL
Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.